Can lenalidomide maintenance lead to increased rates of MRD-negativity?

The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, US, answers the question: Can lenalidomide maintenance lead to increased rates of minimal residual disease-negativity?

Lenalidomide maintenance appears to increase MRD-negativity rates. According to a single-arm phase II study on 100 patients treated with lenalidomide maintenance therapy, a high proportion of patients show evidence of many years sustained MRD-negativity and about 25-30% of patients who enter the study as MRD-positive merge into the group of MRD-negative patients.